At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARQT Arcutis Biotherapeutics Inc.
Pre-Mkt 03-18 08:29:03 EDT
22.72
-0.04
-0.18%
盘前22.77
+0.05+0.22%
08:05 EDT
High22.97Low22.31Vol1.40M
Open22.76D1 Closing22.76Amplitude2.90%
Mkt Cap2.82BTradable Cap2.00BTotal Shares124.03M
T/O31.81MT/O Rate1.59%Tradable Shares88.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting
Reuters  ·  25 minutes ago
Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
TIPRANKS  ·  03-10
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data With Zoryve® (Roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
THOMSON REUTERS  ·  03-10
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data With Zoryve® (Roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
TIPRANKS  ·  03-10
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
TIPRANKS  ·  03-09
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
Press Release: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Dow Jones  ·  03-05
Press Release: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis (ARQT) Earnings Call Signals Scaled Growth
TIPRANKS  ·  03-05
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Arcutis Biotherapeutics Director Keith R Leonard Disposes of Common Shares
Reuters  ·  03-05
Arcutis Biotherapeutics Director Keith R Leonard Disposes of Common Shares
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
TIPRANKS  ·  03-03
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Reuters  ·  03-03
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Arcutis Begins Enrolling Phase 1a/1B Study Evaluating Arq-234, a Cd200r Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
THOMSON REUTERS  ·  03-03
Arcutis Begins Enrolling Phase 1a/1B Study Evaluating Arq-234, a Cd200r Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Arcutis Biotherapeutics Inc. Publishes Transcript of Q4 FY2025 Earnings Call
Reuters  ·  03-03
Arcutis Biotherapeutics Inc. Publishes Transcript of Q4 FY2025 Earnings Call
Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR)
TIPRANKS  ·  03-02
Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR)
MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief
MT Newswires Live  ·  02-27
MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief
Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
TIPRANKS  ·  02-27
Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades
Stock Track  ·  02-27
Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades
Arcutis Biotherapeutics Is Maintained at Buy by Needham
Dow Jones  ·  02-26
Arcutis Biotherapeutics Is Maintained at Buy by Needham
Stock Track | Arcutis Biotherapeutics Soars 5.78% in Pre-Market on Analyst Upgrades Following Strong Earnings
Stock Track  ·  02-26
Stock Track | Arcutis Biotherapeutics Soars 5.78% in Pre-Market on Analyst Upgrades Following Strong Earnings
Arcutis Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $34 From $30
THOMSON REUTERS  ·  02-26
Arcutis Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $34 From $30
Arcutis Biotherapeutics Inc : TD Cowen Raises Target Price to $35 From $30
THOMSON REUTERS  ·  02-26
Arcutis Biotherapeutics Inc : TD Cowen Raises Target Price to $35 From $30

Introduction

Company Name.
Arcutis Biotherapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Issue price:
--